Pharmaceutical

Syndax agrees funding with Royalty Pharma for Niktimvo ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharm...

Injectables manufacturing ushers in a new era of access...

Increasingly, injectable manufacturers recognise that to achieve maximum profita...

Disc teases potential NDA for rare skin disorder drug

In an end-of-Phase II meeting, the FDA indicated support for accelerated approva...

EC fines Teva $502m over multiple sclerosis treatment C...

The European Commission (EC) has imposed a fine of €462.6m ($502m) on Teva Pharm...

US court upholds Avadel’s narcolepsy drug approval amid...

The US District Court upholds the FDA’s approval of Avadel’s Lumryz, dismissing ...

AbbVie and EvolveImmune Therapeutics sign oncology coll...

AbbVie has entered into a partnership and option-to-license agreement with Evolv...

How hybrid models and tech are shaping the future of cl...

Decentralized clinical trials are transforming medical research with more flexib...

Lexicon stock tumbles after FDA AdCom votes against Zyn...

The committee was not convinced that the benefit of Zynquista outweighed the ris...

NCCN visits Vietnam in continued cancer care collaboration

Through a partnership, the NCCN is adapting its Harmonized Guidelines for cancer...

Verastem Oncology submits NDA for ovarian cancer treatment

Verastem Oncology has concluded the rolling submission of a new drug application...

Roche to leverage Dyno Therapeutics tech for novel gene...

With the formation of a new strategic partnership, Dyno Therapeutics is responsi...

Bladder cancer diagnoses to top 300,000 in major market...

Bladder cancer is the ninth most common cancer globally, and the number of diagn...

Biogen and Neomorph enter molecular glue degrader deal

Biogen and Neomorph have partnered to discover and develop molecular glue degrad...

Will the tide turn for the wave of pharma layoffs?

Pharmaceutical management expert Kenneth Getz shares insights on broader trends ...

Pfizer boasts over 30% increase in Q3 revenues against ...

Amidst a share value slump and executive turmoil, Pfizer reported a robust quart...